PCI Biotech: Invitation to Q4 2022 results presentation

13 Feb 2023 15:35 CET

Oslo, Norway, 13 February 2023 - PCI Biotech (OSE: PCIB) invites to an online
presentation of the company's Q4 2022 interim report on Friday 17 February
2023, 08:30am - 09:30am CET (local time).

The presentation will be held as a live webcast and can be accessed through
www.pcibiotech.com. There will be a Q&A session at the end of the presentation
and it will be possible to post written questions through the webcast console or
through a teleconference facilitated for attendees intending to ask questions
verbally during the Q&A session.

The company will be represented by Ronny Skuggedal (CEO/CFO), Anders Høgset
(CSO), and Morten Luhr (BD Manager), and the presentation will be held in
Norwegian.

The interim report and presentation will be made available on www.newsweb.no and
on the company's webpage, www.pcibiotech.com, from 07.00am CET the same day.

For further information, please contact:
Ronny Skuggedal, CEO / CFO
Email: rs@pcibiotech.no
Mobile: +47 9400 5757

About PCI Biotech
PCI Biotech is a biopharmaceutical company focussing on development and
commercialisation of novel therapies through its innovative photochemical
internalisation (PCI) technology platform. PCI induces triggered endosomal
release that is used to unlock the true potential of therapeutic modalities.

The fimaNAc programme utilises the proven capability of the PCI technology for
intracellular delivery of nucleic acids. The technology can be used for most
types of nucleic acids, ranging from oligonucleotides through mRNA and plasmids
to viral vectors. The development of the fimaNAc programme is currently focussed
on selected applications within dermatology and bioprocessing, well suited to
the specific strengths of the PCI technology. The fimaVACC programme aims to
enhance immunotherapy in cancer, by triggered endosomal release of antigens or
nucleic acids encoding antigens, or immunostimulatory factors. For further
information, please visit: www.pcibiotech.com
Contact information: PCI Biotech Holding ASA, Ullernchausséen 64, N-0379
Oslo

Forward-looking statements
This announcement may contain forward-looking statements, which as such are not
historical facts, but are based upon various assumptions, many of which are
based, in turn, upon further assumptions. These assumptions are inherently
subject to significant known and unknown risks, uncertainties and other
important factors. Such risks, uncertainties, contingencies and other important
factors could cause actual events to differ materially from the expectations
expressed or implied in this announcement by such forward-looking statements.
PCI Biotech disclaims any obligation to update or revise any forward-looking
statements, whether as a result of new information, future events or otherwise.

More information:
Access the news on Oslo Bors NewsWeb site